Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: dexmedetomidine hydrochloride

« Back to Dashboard
Dexmedetomidine hydrochloride is the generic ingredient in two branded drugs marketed by Akorn Inc, Mylan Institutional, Par Sterile Products, and Hospira, and is included in four NDAs. There are five patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

There are twelve drug master file entries for dexmedetomidine hydrochloride. Two suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for Generic Name: dexmedetomidine hydrochloride

Tradenames:2
Patents:5
Applicants:4
NDAs:4
Drug Master File Entries: see list12
Suppliers / Packaging: see list5

Pharmacology for Ingredient: dexmedetomidine hydrochloride

Tentative approvals for DEXMEDETOMIDINE HYDROCHLORIDE

Applicant Application No. Form Dosage
<disabled><disabled>INJECTABLE; INJECTION100MCG

Clinical Trials for: dexmedetomidine hydrochloride

Comparison Between Lidocaine, Dexmedetomidine, and Their Combined Infusion in Subjects Undergoing Coronary Artery Bypass Graft
Status: Completed Condition: Unstable Angina; Coronary Artery Bypass Graft; Dexmedetomidine; Lidocaine; Myocardial Injury; Arrhythmia; Blood Electrolyte Balance

Small Doses of Dexmedetomidine for Emergence Agitation
Status: Recruiting Condition: Emergence Agitation

Dexmedetomidine Pharmacokinetics in the Obese
Status: Completed Condition: Obesity

Dexmedetomidine vs Fentanyl for BMT
Status: Completed Condition: Otitis

Dexmedetomidine in Spinal Anesthesia
Status: Completed Condition: Blood Pressure; Anxiety

Dexmedetomidine Sedation With Third Molar Surgery
Status: Terminated Condition: Anesthesia

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-003Mar 13, 2013RXYes8,338,470*PED<disabled>Y<disabled>
Mylan Institutional
DEXMEDETOMIDINE HYDROCHLORIDE
dexmedetomidine hydrochloride
INJECTABLE;INJECTION202881-001Aug 18, 2014RXNo<disabled><disabled>
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-004Nov 14, 2014RXNo8,455,527*PED<disabled>Y<disabled>
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-003Mar 13, 2013RXYes<disabled><disabled>
Hospira
PRECEDEX
dexmedetomidine hydrochloride
INJECTABLE;INJECTION021038-004Nov 14, 2014RXNo8,242,158*PED<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc